The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 1.78 — grey zone — between safe and distressedWatch
- Earnings-manipulation signal · Beneish M -2.70 — no flag raisedOK
- Earnings quality 100/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as BeOne Medicines Ltd. reports it. History and quarterly detail are in the app.
- Product revenue, net$5.3B
- Other revenue$61.0M
Leadership changes
From BeOne Medicines Ltd.'s own filings, the day they're filed.
- Lai Wang · President · appointmenteff. 2025-12-17
- Shalini Sharp · director · appointmenteff. 2024-09-27
- Julia Wang · CFO · departureeff. 2024-07-19
Latest filings
- 8-K · Company announcement2026-06-11
- 8-K · Company announcement2026-05-15
- 10-Q · Quarterly report2026-05-06
- 8-K · Company announcement2026-05-06
- DEF 14A · Annual proxy (pay & governance)2026-04-28
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about BeOne Medicines Ltd., every answer cited🔒
- The Intelligence Brief — added when BeOne Medicines Ltd.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.